Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens

ZHANG Huanqi; LIN Xu; SHEN Shuying; LI Yangling

doi:10.6039/j.issn.1001-0408.2023.16.23

您当前的位置：

首页 >

文章列表页 >

Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens

更新时间：2023-08-24

- Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens
- ZHONGGUO YAOFANG Vol. 34, Issue 16, Pages: 2039-2043(2023)
- 作者机构：
  
  1.浙江大学药学院/临床药学研究中心，杭州　310006
  2.浙江大学医学院附属第一医院胸外科，杭州　310006
  3.浙江大学医学院附属杭州市第一人民医院临床药理研究室/浙江省临床肿瘤药理与毒理学研究重点实验室，杭州　310006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.16.23
  CLC： R979.1;R734.2
- Published：30 August 2023，
  
  Received：28 February 2023，
  
  Revised：24 July 2023，
扫描看全文
章欢琪,林旭,沈姝颖等.小细胞肺癌的临床用药方案现状及潜在靶点药物治疗方案新进展 ^Δ[J].中国药房,2023,34(16):2039-2043.

ZHANG Huanqi,LIN Xu,SHEN Shuying,et al.Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens[J].ZHONGGUO YAOFANG,2023,34(16):2039-2043.
章欢琪,林旭,沈姝颖等.小细胞肺癌的临床用药方案现状及潜在靶点药物治疗方案新进展 ^Δ[J].中国药房,2023,34(16):2039-2043. DOI： 10.6039/j.issn.1001-0408.2023.16.23.

ZHANG Huanqi,LIN Xu,SHEN Shuying,et al.Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens[J].ZHONGGUO YAOFANG,2023,34(16):2039-2043. DOI： 10.6039/j.issn.1001-0408.2023.16.23.

摘要

小细胞肺癌（SCLC）约占肺癌的15%，恶性程度高，异质性和侵袭性均较强。依托泊苷联合铂类是广泛期SCLC标准一线治疗的基础，但存在易耐药、易复发的问题。近年来，新型免疫药物和新型细胞毒性药物的出现在一定程度上提高了SCLC患者的生存率，为复发/难治型SCLC患者带来了治疗希望。本文通过综述SCLC临床用药方案的现状和潜在靶点药物治疗方案的新进展发现，目前SCLC一、二、三线方案包括依托泊苷+卡铂、阿替利珠单抗+依托泊苷+铂类药物、阿得贝利单抗、拓扑替康、多西他赛等，作用靶点主要集中在拓扑异构酶Ⅱ/Ⅰ、DNA、免疫检查点分子程序性死亡受体1/程序性死亡受体配体1、微管蛋白等；潜在靶点药物治疗方案包括阿立塞替+紫杉醇、洛伐妥珠单抗、APG-1252等，作用靶点主要集中在DNA损伤应答通路和免疫通路，可通过极光激酶A等多种潜在靶点来发挥抗肿瘤作用，实现延长患者生存期的治疗目标。

Abstract

mall cell lung cancer （SCLC） accounts for about 15% in lung cancer and is highly malignant， heterogeneous and invasive. Etoposide combined with platinum-based chemotherapy is the basis of standard first-line treatment for extensive-stage SCLC， but suffers from the problem of susceptibility to drug resistance and relapse. In recent years， the emergence of new immunological drugs and novel cytotoxic drugs has improved the survival of SCLC patients to a certain extent， especially bringing therapeutic hope to patients with relapsed/refractory SCLC. In this paper， we review the current clinical drug regimens and the new progress of potential target drug therapeutic regimens for the treatment of SCLC. At present， the first-， second- and third-line schemes of SCLC include etoposide+carboplatin， atezolizumab+etoposide+platinum， adebrelimab， topotecan， docetaxel， etc.； the current drug targets for the treatment of SCLC mainly focus on topoisomerase Ⅱ/Ⅰ， DNA， the immune checkpoint molecules programmed death-1/programmed death-ligand 1， tubulin， etc. The potential target drug therapeutic options include alisertib+paclitaxel， rovalpituzumab， APG-1252， etc.， and mainly focus on DNA damage response pathways and immune pathways， which can achieve the prolongation of patient survival by exerting anti-tumor effects through aurora kinase A and other potential targets.

关键词

小细胞肺癌化疗免疫治疗作用靶点潜在靶点药物治疗方案

Keywords

chemotherapyimmunotherapytherapeutic targetspotential target drug therapeutic options

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

KALEMKERIAN G P，GADGEEL S M. Modern staging of small cell lung cancer[J]. J Natl Compr Canc Netw，2013，11（1）：99-104.

KASHIMA J，OKUMA Y. Advances in biology and novel treatments of SCLC：the four-color problem in uncharted territory[J]. Semin Cancer Biol，2022，86（Pt 2）：386-395.

莫淑芬，许靖靖，李祖设，等. 小细胞肺癌的药物治疗研究进展[J/OL]. 心电图杂志（电子版），2017，6（1）：125-126[2022-12-17]. https：//doc.taixueshu.com/journal/2017-0236xdtzz-d.html?utm_source=doc_sharehttps://doc.taixueshu.com/journal/2017-0236xdtzz-d.html?utm_source=doc_share.

HORN L，MANSFIELD A S，SZCZĘSNA A，et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med，2018，379（23）：2220-2229.

PAZ-ARES L，DVORKIN M，CHEN Y B，et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer（CASPIAN）：a randomised，controlled，open-label，phase 3 trial[J]. Lancet，2019，394（10212）：1929-1939.

WANG J，ZHOU C C，YAO W X，et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer（CAPSTONE-1）：a multicentre，randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2022，23（6）：739-747.

李梦洁，黄鼎智. 2022年度小细胞肺癌治疗进展[J/OL]. 肿瘤综合治疗电子杂志，2023，9（1）：18-23[2022-12-17].https：//www.zhangqiaokeyan.com/academic-journal-cn_ cancer-comprehensive-therapy-e-magazine_thesis/020121-00706127.htmlhttps://www.zhangqiaokeyan.com/academic-journal-cn_cancer-comprehensive-therapy-e-magazine_thesis/020121-00706127.html. DOI：10.12151/JMCM.2023.01-03http://dx.doi.org/10.12151/JMCM.2023.01-03.

READY N E，OTT P A，HELLMANN M D，et al. Nivo-lumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer：results from the checkmate 032 randomized cohort[J]. J Thorac Oncol，2020，15（3）：426-435.

崔晓霞，张力. 小细胞肺癌诊疗新进展[J]. 中国肺癌杂志，2019，22（6）：355-362.

SAYED R E，DARSA H E. Therapeutic modalities in small cell lung cancer：a paradigm shift after decades of quiescence[J]. Expert Opin Pharmacother，2022，23（5）：583-597.

阿丽亚·奥斯曼，王效刚，刘俊远，等. 小细胞肺癌内科治疗新进展[J]. 现代肿瘤医学，2023，31（7）：1362-1366.

XIA X H，PI W H，LAN Y L，et al. Synergistic antitumor effects of anlotinib combined with oral 5-fluorouracil/S-1 via inhibiting Src/AKT signaling pathway in small-cell lung cancer[J]. Anal Cell Pathol，2022，2022：4484211.

郭家毓，呼群. 小细胞肺癌免疫治疗研究进展[J]. 陕西医学杂志，2023，52（1）：118-121.

ROTTENBERG S，DISLER C，PEREGO P. The redisco-very of platinum-based cancer therapy[J]. Nat Rev Cancer，2021，21（1）：37-50.

PILIÉ P G，TANG C，MILLS G B，et al. State-of-the-art strategies for targeting the DNA damage response in cancer[J]. Nat Rev Clin Oncol，2019，16（2）：81-104.

BYERS L A，WANG J，NILSSON M B，et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1[J]. Cancer Discov，2012，2（9）：798-811.

SEN T，TONG P，STEWART C A，et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination acti-vity with cisplatin or olaparib[J]. Cancer Res，2017，77（14）：3870-3884.

HENDRIKS L E L，MENIS J，RECK M. Prospects of targeted and immune therapies in SCLC[J]. Expert Rev Anticancer Ther，2019，19（2）：151-167.

SOS M L，DIETLEIN F，PEIFER M，et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer[J]. Proc Natl Acad Sci U S A，2012，109（42）：17034-17039.

SERZAN M T，FARID S，LIU S V. Drugs in development for small cell lung cancer[J]. J Thorac Dis，2020，12（10）：6298-6307.

HERZOG B H，DEVARAKONDA S，GOVINDAN R. Overcoming chemotherapy resistance in SCLC[J]. J Thorac Oncol，2021，16（12）：2002-2015.

PIETANZA M C，WAQAR S N，KRUG L M，et al. Randomized，double-blind，phase Ⅱ study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer[J]. J Clin Oncol，2018，36（23）：2386-2394.

MURAI J，TANG S W，LEO E，et al. SLFN11 blocks stressed replication Forks independently of ATR[J]. Mol Cell，2018，69（3）：371-384.

SEN T，RODRIGUEZ B L，CHEN L M，et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer[J]. Cancer Discov，2019，9（5）：646-661.

SEN T，TONG P，DIAO L X，et al. Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer[J]. Clin Cancer Res，2017，23（20）：6239-6253.

PARK S，SHIM J，JUNG H，et al. Biomarker driven phase Ⅱ umbrella trial study of AZD1775，AZD2014，AZD2811 monotherapy in relapsed small cell lung cancer[J]. J Clin Oncol，2019，37（15_suppl）：8514.

KE Z Y，LIANG A L，LIU Y J. Cell cycle checkpoint kinase and drug resistance of lung cancer[J]. Zhongguo Fei Ai Za Zhi，2021，24（4）：265-270.

葛凡，孙建，黄璐. 小分子周期蛋白依赖性激酶4/6抑制剂药物及其专利研究[J]. 中国医药工业杂志，2022，53（4）：464-473.

LEONETTI A，FACCHINETTI F，MINARI R，et al. Notch pathway in small-cell lung cancer：from preclinical evidence to therapeutic challenges[J]. Cell Oncol，2019，42（3）：261-273.

GIFFIN M J，COOKE K，LOBENHOFER E K，et al. AMG 757，a half-life extended，DLL3-targeted bispecific T-cell engager，shows high potency and sensitivity in preclinical models of small-cell lung cancer[J]. Clin Cancer Res，2021，27（5）：1526-1537.

ZHAN J B，HAN Q，WANG K Y. Development of antibody therapeutics for small cell lung cancer[J]. Expert Opin Investig Drugs，2013，22（2）：235-244.

BREZICKA T，BERGMAN B，OLLING S，et al. Reacti-vity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues[J]. Lung Cancer，2000，28（1）：29-36.

CHU Q，LEIGHL N B，SURMONT V，et al. BMS-986012，an anti-fucosyl-GM1 monoclonal antibody as monotherapy or in combination with nivolumab in relapsed/refractory SCLC：results from a first-in-human phase 1/2 study[J]. JTO Clin Res Rep，2022，3（11）：100400.

谢君鸿，何晶晶，周鹏辉. 合成生物学与工程化T细胞治疗[J]. 合成生物学，2023，4（2）：373-393.

WALIA H K，SHARMA P，SINGH N，et al. Immunotherapy in small cell lung cancer treatment：a promising headway for future perspective[J]. Curr Treat Options Oncol，2022，23（2）：268-294.

BIANCO A，D’AGNANO V，MATERA M G，et al. Immune checkpoint inhibitors：a new landscape for extensive stage small cell lung cancer treatment[J]. Expert Rev Respir Med，2021，15（11）：1415-1425.

戢福云，钱桂生，钱频，等. bcl-2对人小细胞肺癌细胞系H446/DDP多药耐药性的影响[J]. 中华结核和呼吸杂志，2006，29（3）：156-160.

LAKHANI N J，RASCO D W，ZENG Q，et al. First-in-human study of palcitoclax（APG-1252），a novel dual Bcl-2/Bcl-xL inhibitor，demonstrated advantages in platelet safety while maintaining anticancer effect in US patients with metastatic solid tumors[EB/OL]. [2023-02-10]. http：//www.mhn24.com/7673.htmlhttp://www.mhn24.com/7673.html.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of chemotherapy combined with camrelizumab in patients with inoperable microsatellite stable type colorectal cancer

Related Author

YU Weifei

WANG Xiaoqiu

ZHAO Liping

FENG Jihong

ZHOU Jueyi

Related Institution

Dept. of Chemoradiotherapy， Lishui People’s Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰